• New 10mg strength offers increased treatment flexibility and more convenient dosage form
• Comparable quality, safety and efficacy combined with significant cost savings
• Approval further demonstrates Sandoz leadership in high quality follow-on biologics

Princeton, New Jersey: September 3, 2008 -- Sandoz has received US Food and Drug Administration approval for its Omnitrope® Pen 10 with liquid cartridge. Omnitrope, a somatropin, is approved for long-term treatment of pediatric patients who have growth failure and long-term replacement therapy in adults with growth hormone deficiency.